Bladder Cancer, Cancer, Colorectal Cancer, Non Small Cell Lung Cancer, Solid Tumor
Conditions
Keywords
minimal residual disease, MRD, ctDNA, circulating tumor DNA
Brief summary
This study recruits patient with solid tumor types for sample collection and monitoring. Participants will provide blood and archival tissue samples in order to create a Personalized Cancer Monitoring (PCM) assay. This assay will be used to detect circulating tumor DNA (ctDNA) levels in the blood over time and hopefully contribute to improvements in residual disease detection methods for future patients. Results from this assay will be provided to participants and providers but providers are not asked to change patient care based on this information.
Detailed description
This study involves collection of tumor tissue (from a standard biopsy and/or surgery) as well as blood samples over time in order to allow the creation of a Personalized Cancer Monitoring (PCM) assay. Additional blood samples are taken throughout the patient's treatment and follow-up period. Each participant will submit one blood sample when they begin participation in the research study. Participants will be asked to submit follow up samples several times per year (annually, at minimum), with the exact frequency varying by stage and type of cancer. In general, participants will not be asked to come into the clinic more frequently than their already needed clinic visits. If the cancer-specific mutations identified by the PCM are detected in the blood samples provided as part of the study, this may would suggests that residual cancer may be present. This is an observational study comparing MRD results to standard of care methods and collecting provider and patient perspectives, using surveys. Physicians will be informed of all PCM results in the form of a clinical report. Physicians are not asked to base treatment decisions on these results.
Interventions
DIAGNOSTIC_TESTPersonalized Cancer Monitoring (PCM)
personalized molecular test for solid tumor cancer patients that may detect the presence of circulating tumor DNA (ctDNA) and molecular residual disease (MRD), also known as minimal residual disease
Sponsors
Invitae Corporation
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Stated ability to give informed consent by participant. 2. Stated health status of participant as healthy enough to provide Biological Material. 3. Individuals diagnosed with solid cancer of any type, including but not limited to colorectal, non-small cell lung, breast, ovarian and bladder cancers, regardless of the length of time since diagnosis and regardless of previous therapies. 4. Participant is of any biological sex and \>18 years of age 5. Participant has not undergone a blood transfusion within the previous three weeks
Exclusion criteria
1. Participants who are deemed medically unstable 2. Participants who are deemed to be difficult to draw blood from. 3. Participants who are \<18 years of age 4. Participants diagnosed with CNS cancers, sarcomas or hematologic malignancies such as leukemia or lymphoma . 5. Participants with more than one primary cancer 6. Participants with FFPE slides older than 10 years 7. Participants who are pregnant 8. Any other reason that, in the Investigator's judgment, that would preclude the participant from being able to participate in the study 9. Participants for which a pathology report is not available
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | Through study completion, up to 5 years |
| Relapse Free Survival | Measured through study completion, assessed yearly up to 3 years |
Countries
United States
Outcome results
None listed